GV971-007 - Phase 3 clinical trial studying GV-971

• Research type

  Research Study

• Full title

  A Phase 3, multi-center, randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the efficacy and safety of sodium oligomannate (GV-971) in treatment of mild to moderate Alzheimer’s disease (GREEN MEMORY: GREen Valley 971 EvaluatioN Memory)

• IRAS ID

  1003238

• Contact name

  Roy Jones

• Contact email

  r.w.jones@bath.ac.uk

• Sponsor organisation

  Shanghai Green Valley Pharmaceutical Co., Ltd

• Eudract number

  2020-001755-41

• REC name

  London - Westminster Research Ethics Committee

• REC reference

  20/LO/1138

• Date of REC Opinion

  17 Dec 2020

• REC opinion

  Further Information Unfavourable Opinion